165 related articles for article (PubMed ID: 10415076)
1. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine.
Rosenberg SA; Yang JC; Schwartzentruber DJ; Hwu P; Marincola FM; Topalian SL; Restifo NP; Sznol M; Schwarz SL; Spiess PJ; Wunderlich JR; Seipp CA; Einhorn JH; Rogers-Freezer L; White DE
J Immunol; 1999 Aug; 163(3):1690-5. PubMed ID: 10415076
[TBL] [Abstract][Full Text] [Related]
2. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
3. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA
Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901.
Roberts JD; Niedzwiecki D; Carson WE; Chapman PB; Gajewski TF; Ernstoff MS; Hodi FS; Shea C; Leong SP; Johnson J; Zhang D; Houghton A; Haluska FG;
J Immunother; 2006; 29(1):95-101. PubMed ID: 16365605
[TBL] [Abstract][Full Text] [Related]
5. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity.
Yang S; Linette GP; Longerich S; Haluska FG
J Immunol; 2002 Jul; 169(1):531-9. PubMed ID: 12077285
[TBL] [Abstract][Full Text] [Related]
6. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
Chianese-Bullock KA; Pressley J; Garbee C; Hibbitts S; Murphy C; Yamshchikov G; Petroni GR; Bissonette EA; Neese PY; Grosh WW; Merrill P; Fink R; Woodson EM; Wiernasz CJ; Patterson JW; Slingluff CL
J Immunol; 2005 Mar; 174(5):3080-6. PubMed ID: 15728523
[TBL] [Abstract][Full Text] [Related]
7. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
Slingluff CL; Petroni GR; Yamshchikov GV; Barnd DL; Eastham S; Galavotti H; Patterson JW; Deacon DH; Hibbitts S; Teates D; Neese PY; Grosh WW; Chianese-Bullock KA; Woodson EM; Wiernasz CJ; Merrill P; Gibson J; Ross M; Engelhard VH
J Clin Oncol; 2003 Nov; 21(21):4016-26. PubMed ID: 14581425
[TBL] [Abstract][Full Text] [Related]
8. Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases.
Panelli MC; Riker A; Kammula U; Wang E; Lee KH; Rosenberg SA; Marincola FM
J Immunol; 2000 Jan; 164(1):495-504. PubMed ID: 10605047
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses.
Smith JW; Walker EB; Fox BA; Haley D; Wisner KP; Doran T; Fisher B; Justice L; Wood W; Vetto J; Maecker H; Dols A; Meijer S; Hu HM; Romero P; Alvord WG; Urba WJ
J Clin Oncol; 2003 Apr; 21(8):1562-73. PubMed ID: 12697882
[TBL] [Abstract][Full Text] [Related]
10. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
[TBL] [Abstract][Full Text] [Related]
11. Long-term survival of anti-tumor lymphocytes generated by vaccination of patients with melanoma with a peptide vaccine.
Stewart JH; Rosenberg SA
J Immunother; 2000; 23(4):401-4. PubMed ID: 10916748
[TBL] [Abstract][Full Text] [Related]
12. Kinetics of TCR use in response to repeated epitope-specific immunization.
Monsurrò V; Nielsen MB; Perez-Diez A; Dudley ME; Wang E; Rosenberg SA; Marincola FM
J Immunol; 2001 May; 166(9):5817-25. PubMed ID: 11313426
[TBL] [Abstract][Full Text] [Related]
13. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression.
Lee KH; Wang E; Nielsen MB; Wunderlich J; Migueles S; Connors M; Steinberg SM; Rosenberg SA; Marincola FM
J Immunol; 1999 Dec; 163(11):6292-300. PubMed ID: 10570323
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
[TBL] [Abstract][Full Text] [Related]
15. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides.
Salgaller ML; Marincola FM; Cormier JN; Rosenberg SA
Cancer Res; 1996 Oct; 56(20):4749-57. PubMed ID: 8840994
[TBL] [Abstract][Full Text] [Related]
16. T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants.
Schaed SG; Klimek VM; Panageas KS; Musselli CM; Butterworth L; Hwu WJ; Livingston PO; Williams L; Lewis JJ; Houghton AN; Chapman PB
Clin Cancer Res; 2002 May; 8(5):967-72. PubMed ID: 12006508
[TBL] [Abstract][Full Text] [Related]
17. Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue.
Clay TM; Custer MC; McKee MD; Parkhurst M; Robbins PF; Kerstann K; Wunderlich J; Rosenberg SA; Nishimura MI
J Immunol; 1999 Feb; 162(3):1749-55. PubMed ID: 9973438
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100.
Panelli MC; Wunderlich J; Jeffries J; Wang E; Mixon A; Rosenberg SA; Marincola FM
J Immunother; 2000; 23(4):487-98. PubMed ID: 10916759
[TBL] [Abstract][Full Text] [Related]
19. The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides.
Harris RC; Chianese-Bullock KA; Petroni GR; Schaefer JT; Brill LB; Molhoek KR; Deacon DH; Patterson JW; Slingluff CL
J Immunother; 2012 Jan; 35(1):78-88. PubMed ID: 22130163
[TBL] [Abstract][Full Text] [Related]
20. Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2.
Chianese-Bullock KA; Woodson EM; Tao H; Boerner SA; Smolkin M; Grosh WW; Neese PY; Merrill P; Petroni GR; Slingluff CL
J Immunother; 2005; 28(4):412-9. PubMed ID: 16000961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
